PHOENIX, Ariz. — Pete Pharma and Fagron, Inc. have entered into a strategic distribution and commercialization partnership aimed at expanding access to pharmaceutical 3D printing technology across the United States and Canada.
Under the agreement, Fagron will serve as the exclusive reseller of Pete Pharma’s 3D pharmaceutical printing platform in North America, targeting both 503A and 503B compounding pharmacies.
The collaboration combines Pete Pharma’s advanced 3D printing platform—developed in partnership with FABRx and including the M3DIMAKER hardware, software infrastructure, and delivery systems—with Fagron’s established commercial network and relationships across the compounding industry.
The partnership is designed to accelerate adoption of automated solid dosage manufacturing, enabling pharmacies to produce a wider range of formulations, including immediate-release tablets, extended-release medications, oral films, troches, water-dissolvable tablets, chewables, and suppositories.
“This partnership represents a significant step in scaling access to pharmaceutical 3D printing technology,” said Marc Joiner, Co-Founder of Pete Pharma. “Fagron has built a strong global presence within the compounding industry. By aligning our platform with their commercial infrastructure, we are creating a clear pathway for pharmacies to adopt advanced manufacturing capabilities and expand their product offerings.”
Fagron executives said the agreement supports efforts to bring more scalable and innovative manufacturing solutions to pharmacies.
“This collaboration allows us to bring next-generation pharmaceutical manufacturing solutions to our customers in a structured and scalable way,” said Andrew Allan, Vice President of Sales at Fagron. “Pete Pharma’s platform represents a meaningful advancement in how compounded medications can be developed and delivered. We are excited to support the expansion of this technology across our network,” said Amy Jones, Business Leader at Fagron.
Both companies said the partnership reflects a shared goal of modernizing pharmaceutical compounding through innovation and scalable infrastructure, with the aim of helping pharmacies improve efficiency, increase production capacity, and deliver more tailored therapies to patients.
